Ticker Details
Ovid Therapeutics Inc. Ovid Therapeutics Inc is a US-based biopharmaceutical company. The firm is engaged primarily in developing medicines for patients suffering with rare neurological disorders.
IPO Date:	May 10, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$546.83M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.14 | 3.86%
Avg Daily Range (30 D):	$0.08 | 3.07%
Avg Daily Range (90 D):	$0.08 | 3.33%

Institutional Daily Volume
Avg Daily Volume:	.69M
Avg Daily Volume (30 D):	1.31M
Avg Daily Volume (90 D):	1.79M

Trade Size
Avg Trade Size (Sh.):	215
Avg Trade Size (Sh.) (30 D):	133
Avg Trade Size (Sh.) (90 D):	139

Institutional Trades
Total Institutional Trades:	166
Avg Institutional Trade:	$2.23M
Avg Institutional Trade (30 D):	$1.46M
Avg Institutional Trade (90 D):	$2.85M
Avg Institutional Trade Volume:	.7M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.27M
Avg Closing Trade (30 D):	$.69M
Avg Closing Trade (90 D):	$3.26M
Avg Closing Volume:	989.59K

News

Mar 18, 2026 @ 6:17 PM Here's Why Ovid Therapeutics Stock Popped Higher T... Source: Lee Samaha

Mar 18, 2026 @ 10:00 AM Ovid Therapeutics Announces Pricing of $60 Million... Source: Na

Nov 12, 2025 @ 12:00 PM Ovid Therapeutics Announces Planned Leadership Suc... Source: Ovid Therapeutics

Feb 27, 2025 @ 1:00 PM Ovid Therapeutics to Present at the TD Cowen 45th ... Source: N/A

Feb 20, 2025 @ 6:00 PM Epilepsy Market Assessment in the 7MM by 2034 ââ‚... Source: Delveinsight

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS
Diluted EPS
Revenue	$1.58M	$.73M	$M
Gross Profit
Net Income / Loss	$-34.49M	$-15.01M	$-16.99M
Operating Income / Loss	$-58.36M	$-15.7M	$-17.85M
Cost of Revenue
Net Cash Flow	$-16.8M	$-82.73M	$81.03M
PE Ratio